DOI record:
{
"DOI": "10.2807/1560-7917.es.2021.26.9.2001202",
"ISSN": [
"1560-7917"
],
"URL": "http://dx.doi.org/10.2807/1560-7917.ES.2021.26.9.2001202",
"abstract": "<jats:sec>\n <jats:title>Background</jats:title>\n <jats:p>Several clinical trials have assessed the protective potential of chloroquine and hydroxychloroquine. Chronic exposure to such drugs might lower the risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or severe coronavirus disease (COVID-19).</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Aim</jats:title>\n <jats:p>To assess COVID-19 incidence and risk of hospitalisation in a cohort of patients chronically taking chloroquine/hydroxychloroquine.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Methods</jats:title>\n <jats:p>We used linked health administration databases to follow a cohort of patients with chronic prescription of hydroxychloroquine/chloroquine and a control cohort matched by age, sex and primary care service area, between 1 January and 30 April 2020. COVID-19 cases were identified using International Classification of Diseases 10 codes.</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Results</jats:title>\n <jats:p>We analysed a cohort of 6,746 patients (80% female) with active prescriptions for hydroxychloroquine/chloroquine, and 13,492 controls. During follow-up, there were 97 (1.4%) COVID-19 cases in the exposed cohort and 183 (1.4%) among controls. The incidence rate was very similar between the two groups (12.05 vs 11.35 cases/100,000 person-days). The exposed cohort was not at lower risk of infection compared with controls (hazard ratio (HR): 1.08; 95% confidence interval (CI): 0.83–1.44; p = 0.50). Forty cases (0.6%) were admitted to hospital in the exposed cohort and 50 (0.4%) in the control cohort, suggesting a higher hospitalisation rate in the former, though differences were not confirmed after adjustment (HR: 1·46; 95% CI: 0.91–2.34; p = 0.10).</jats:p>\n </jats:sec>\n <jats:sec>\n <jats:title>Conclusions</jats:title>\n <jats:p>Patients chronically exposed to chloroquine/hydroxychloroquine did not differ in risk of COVID-19 nor hospitalisation, compared with controls. As controls were mainly female, findings might not be generalisable to a male population.</jats:p>\n </jats:sec>",
"author": [
{
"ORCID": "http://orcid.org/0000-0001-7547-0291",
"affiliation": [
{
"name": "These authors contributed equally"
},
{
"name": "Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut Generalitat de Catalunya, Carrer de Roc Boronat 81-95, Barcelona, Spain"
}
],
"authenticated-orcid": false,
"family": "Vivanco-Hidalgo",
"given": "Rosa Maria",
"sequence": "first"
},
{
"affiliation": [
{
"name": "Infectious Diseases Department, Hospital Universitario Vall d'Hebron, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain"
},
{
"name": "These authors contributed equally"
}
],
"family": "Molina",
"given": "Israel",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut Generalitat de Catalunya, Carrer de Roc Boronat 81-95, Barcelona, Spain"
}
],
"family": "Martinez",
"given": "Elisenda",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut Generalitat de Catalunya, Carrer de Roc Boronat 81-95, Barcelona, Spain"
}
],
"family": "Roman-Viñas",
"given": "Ramón",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Infectious Diseases Department, Hospital Universitario Vall d'Hebron, PROSICS Barcelona, Universitat Autònoma de Barcelona, Barcelona, Spain"
}
],
"family": "Sánchez-Montalvá",
"given": "Adrián",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Institut de Recerca Biomedica de Lleida, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain"
},
{
"name": "Unitat de Genètica Humana, Departament de Ciències Mèdiques Bàsiques, Universitat de Lleida, Av. Alcalde Rovira Roure, 80, 25198, Lleida, Spain"
}
],
"family": "Fibla",
"given": "Joan",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Av. de Can Domènech, 737, 08193 Cerdanyola del Vallès, Barcelona, Spain"
},
{
"name": "Gerència del Medicament – Àrea Assistencial, Servei Català de la Salut, Travessera de les Corts, 131-159, 08028 Barcelona, Spain"
}
],
"family": "Pontes",
"given": "Caridad",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Departament de Salut Generalitat de Catalunya, Carrer de Roc Boronat 81-95, Barcelona, Spain"
}
],
"family": "Velasco Muñoz",
"given": "César",
"sequence": "additional"
},
{
"affiliation": [],
"name": "on behalf of the Real World Data Working Group",
"sequence": "additional"
}
],
"container-title": "Eurosurveillance",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
3,
5
]
],
"date-time": "2021-03-05T11:20:18Z",
"timestamp": 1614943218000
},
"deposited": {
"date-parts": [
[
2022,
9,
15
]
],
"date-time": "2022-09-15T10:38:26Z",
"timestamp": 1663238306000
},
"indexed": {
"date-parts": [
[
2024,
3,
28
]
],
"date-time": "2024-03-28T02:34:54Z",
"timestamp": 1711593294776
},
"is-referenced-by-count": 8,
"issue": "9",
"issued": {
"date-parts": [
[
2021,
3,
4
]
]
},
"journal-issue": {
"issue": "9",
"published-print": {
"date-parts": [
[
2021,
3,
4
]
]
}
},
"language": "en",
"license": [
{
"URL": "http://creativecommons.org/licenses/by/4.0/",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2021,
3,
4
]
],
"date-time": "2021-03-04T00:00:00Z",
"timestamp": 1614816000000
}
}
],
"member": "7995",
"original-title": [],
"prefix": "10.2807",
"published": {
"date-parts": [
[
2021,
3,
4
]
]
},
"published-print": {
"date-parts": [
[
2021,
3,
4
]
]
},
"publisher": "European Centre for Disease Control and Prevention (ECDC)",
"reference": [
{
"key": "r1",
"unstructured": "World Health Organization (WHO). Novel Coronavirus (2019-nCoV) situation reports. Geneva: WHO; 2020. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports"
},
{
"article-title": "[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]",
"first-page": "185",
"issue": "3",
"journal-title": "Zhonghua Jie He He Hu Xi Za Zhi",
"key": "r2",
"volume": "43",
"year": "2020"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105949",
"article-title": "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.",
"author": "Gautret",
"doi-asserted-by": "crossref",
"issue": "1",
"journal-title": "Int J Antimicrob Agents",
"key": "r3",
"volume": "56",
"year": "2020"
},
{
"DOI": "10.1093/cid/ciaa237",
"article-title": "In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).",
"author": "Yao",
"doi-asserted-by": "crossref",
"first-page": "732",
"issue": "15",
"journal-title": "Clin Infect Dis",
"key": "r4",
"volume": "71",
"year": "2020"
},
{
"DOI": "10.1093/jac/dkaa114",
"article-title": "COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.",
"author": "Zhou",
"doi-asserted-by": "crossref",
"first-page": "1667",
"issue": "7",
"journal-title": "J Antimicrob Chemother",
"key": "r5",
"volume": "75",
"year": "2020"
},
{
"DOI": "10.1016/j.autrev.2020.102566",
"article-title": "Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis.",
"author": "Gendelman",
"doi-asserted-by": "crossref",
"issue": "7",
"journal-title": "Autoimmun Rev",
"key": "r6",
"volume": "19",
"year": "2020"
},
{
"article-title": "Chemotherapy of malaria and resistance to antimalarials. Report of a WHO scientific group.",
"first-page": "1",
"journal-title": "World Health Organ Tech Rep Ser",
"key": "r7",
"volume": "529",
"year": "1973"
},
{
"DOI": "10.1111/j.1365-3156.2006.01778.x",
"article-title": "Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, double-blind, placebo-controlled trial.",
"author": "Villegas",
"doi-asserted-by": "crossref",
"first-page": "209",
"issue": "2",
"journal-title": "Trop Med Int Health",
"key": "r8",
"volume": "12",
"year": "2007"
},
{
"DOI": "10.1016/j.ophtha.2016.01.058",
"article-title": "Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).",
"author": "Marmor",
"doi-asserted-by": "crossref",
"first-page": "1386",
"issue": "6",
"journal-title": "Ophthalmology",
"key": "r9",
"volume": "123",
"year": "2016"
},
{
"DOI": "10.2174/0929867324666170316115938",
"article-title": "The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.",
"author": "Hu",
"doi-asserted-by": "crossref",
"first-page": "2241",
"issue": "20",
"journal-title": "Curr Med Chem",
"key": "r10",
"volume": "24",
"year": "2017"
},
{
"DOI": "10.1038/nrrheum.2009.182",
"article-title": "Treatment of rheumatoid arthritis: state of the art 2009.",
"author": "van Vollenhoven",
"doi-asserted-by": "crossref",
"first-page": "531",
"issue": "10",
"journal-title": "Nat Rev Rheumatol",
"key": "r11",
"volume": "5",
"year": "2009"
},
{
"DOI": "10.1038/nrneph.2011.150",
"article-title": "The role of antimalarial agents in the treatment of SLE and lupus nephritis.",
"author": "Lee",
"doi-asserted-by": "crossref",
"first-page": "718",
"issue": "12",
"journal-title": "Nat Rev Nephrol",
"key": "r12",
"volume": "7",
"year": "2011"
},
{
"key": "r13",
"unstructured": "World Health Organization (WHO). International classification of diseases: [9th] ninth revision, basic tabulation list with alphabetic index. Geneva: WHO; 1978. Available from: https://apps.who.int/iris/handle/10665/39473"
},
{
"key": "r14",
"unstructured": "World Health Organization (WHO). ICD-10: international statistical classification of diseases and related health problems: tenth revision, 2nd ed. Geneva: WHO; 2004. Available from: https://apps.who.int/iris/handle/10665/4298015"
},
{
"DOI": "10.1016/j.aprim.2016.06.003",
"article-title": "grupo colaborativo GMA.",
"author": "Monterde",
"doi-asserted-by": "crossref",
"first-page": "674",
"journal-title": "Aten Primaria",
"key": "r15",
"volume": "48",
"year": "2016"
},
{
"DOI": "10.1016/j.gaceta.2018.07.015",
"article-title": "[A deprivation index to reform the financing model of primary care in Catalonia (Spain)]",
"author": "Colls",
"doi-asserted-by": "crossref",
"first-page": "44",
"issue": "1",
"journal-title": "Gac Sanit",
"key": "r16",
"volume": "34",
"year": "2020"
},
{
"key": "r17",
"unstructured": "R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: http://www.R-project.org/"
},
{
"DOI": "10.1136/bmj.m1849",
"article-title": "Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial.",
"author": "Tang",
"doi-asserted-by": "crossref",
"first-page": "m1849",
"journal-title": "BMJ",
"key": "r18",
"volume": "369",
"year": "2020"
},
{
"DOI": "10.1136/bmj.m1844",
"article-title": "Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.",
"author": "Mahévas",
"doi-asserted-by": "crossref",
"first-page": "m1844",
"journal-title": "BMJ",
"key": "r19",
"volume": "369",
"year": "2020"
},
{
"DOI": "10.1101/2020.04.16.20065920",
"doi-asserted-by": "crossref",
"key": "r20",
"unstructured": "Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19; medRxiv 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v2"
},
{
"DOI": "10.1101/2020.04.07.20056424",
"article-title": "Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial",
"author": "Silva Borba",
"doi-asserted-by": "crossref",
"key": "r21",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2016638",
"article-title": "A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.",
"author": "Boulware",
"doi-asserted-by": "crossref",
"first-page": "517",
"issue": "6",
"journal-title": "N Engl J Med",
"key": "r22",
"volume": "383",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2021801",
"article-title": "A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.",
"author": "Mitjà",
"doi-asserted-by": "crossref",
"first-page": "417",
"issue": "5",
"journal-title": "N Engl J Med",
"key": "r23",
"volume": "384",
"year": "2021"
},
{
"key": "r24",
"unstructured": "ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29. Identifier NCT04334928, Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS). ClinicalTrials.gov; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04334928"
},
{
"DOI": "10.1001/jama.2020.8524",
"article-title": "Nursing Home Care in Crisis in the Wake of COVID-19.",
"author": "Grabowski",
"doi-asserted-by": "crossref",
"first-page": "23",
"issue": "1",
"journal-title": "JAMA",
"key": "r25",
"volume": "324",
"year": "2020"
},
{
"key": "r26",
"unstructured": "Kaiser Family Foundation (KFF). State Reporting of Cases and Deaths Due to COVID-19 in Long-Term Care Facilities. Washington, DC: KFF; 2020. Available from: https://www.kff.org/coronavirus-covid-19/issue-brief/state-reporting-of-cases-and-deaths-due-to-covid-19-in-long-term-care-facilities"
},
{
"DOI": "10.1101/2020.05.04.20090878",
"doi-asserted-by": "crossref",
"key": "r27",
"unstructured": "Chow DS, Soun J, Gavis-Bloom J, Weinberg B, Chang P, Mutasa S, et al. The disproportionate rise in COVID-19 cases among Hispanic/Latinx in disadvantaged communities of Orange County, California: A socioeconomic case-series; medRxiv 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.05.04.20090878v1"
},
{
"DOI": "10.1016/S0140-6736(20)30893-X",
"article-title": "COVID-19 exacerbating inequalities in the US.",
"author": "Dorn",
"doi-asserted-by": "crossref",
"first-page": "1243",
"issue": "10232",
"journal-title": "Lancet",
"key": "r28",
"volume": "395",
"year": "2020"
},
{
"key": "r29",
"unstructured": "Ministerio de Sanidad. Real Decreto-ley 7/2018, 27 de julio, sobre el acceso universal al Sistema Nacional de Salud. BOE-A-2018-10752. Madrid: Ministerio de Sanidad; 2018. Spanish. Available from: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2018-10752"
}
],
"reference-count": 29,
"references-count": 29,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.9.2001202"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Virology",
"Public Health, Environmental and Occupational Health",
"Epidemiology"
],
"subtitle": [],
"title": "Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.2807/1560-7917.es.crp2020",
"volume": "26"
}
